Results 111 to 120 of about 8,557 (171)

Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data

Health Economics Review
Background Biosimilars are biologic drugs that have the potential to increase the efficiency of healthcare spending and curb drug-related cost increases.
Marko Krstic, Jean-Christophe Devaud, Farshid Sadeghipour, Joachim Marti   +3 more
doaj   +1 more source

A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Gastro Hep Advances
Background and Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route of administration. This is a
Alejandro Nieto Dominguez, Abhishek Bhurwal, Hemant Mutneja, Sarah E. Eichinger, Bhanu Pinnam, Daniel Guifarro Rivera, Chun-Wei Pan   +6 more
doaj   +1 more source

Economic aspects of biosimilar competition in Hungary — The treatment of rheumatic disorders [PDF]

, 2017
Biologicals are the fastest growing segment of the global pharmaceutical market, reaching 199 billion USD sales per year with 9.8% 10-year compound annual growth rate (CAGR).
Zrubka, Zsombor
core   +1 more source

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability

Drug Design, Development and Therapy, 2017
Andrea Becciolini,1 Maria Gabriella Raimondo,2 Chiara Crotti,2 Elena Agape,2 Martina Biggioggero,2 Ennio Giulio Favalli1 1Department of Rheumatology, 2Department of Clinical Sciences and Health Community, University of Milan, Division of Rheumatology ...
Becciolini A, Raimondo MG, Crotti C, Agape E, Biggioggero M, Favalli EG   +5 more
doaj  

Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies. [PDF]

Drug Saf, 2023
Takeuchi T, Nishikawa K, Yamada F, Morita A, Ohtsuki M, Suzuki Y, Watanabe M, Yamanaka H, Hibi T.   +8 more
europepmc   +1 more source

Trading between perceived risks and benefits related to biosimilar biological treatment in Crohn’s disease; discrete choice experiment among gastroenterologists [PDF]

, 2015
Objective: The objective of the study is to explore preferences of gastroenterologists for biosimilar drugs in Crohn’s Disease and reveal trade-offs between the perceived risks and benefits related to biosimilar drugs.
Baji, Petra, Brodszky, Valentin, Golovics, Petra A., Gulácsi, László, Lakatos, Péter L., Lovász, Barbara D., Péntek, Márta, Rencz, Fanni   +7 more
core  

Desmoplastic Small Round Cell Tumor of Stomach

Case Reports in Gastrointestinal Medicine, 2013
Desmoplastic small round cell tumor (DSRCT) is an extremely uncommon, highly aggressive, and malignant mesenchymal neoplasm of undetermined histogenesis. Less than 200 case reports have been documented in literature so far.
Ahmed Abu-Zaid, Ayman Azzam, Asma AlNajjar, Hussa Al-Hussaini, Tarek Amin   +4 more
doaj   +1 more source

Biosimilar CT-P13 in treating ulcerative colitis in the real world [PDF]

Minerva Gastroenterology, 2017
RIBALDONE, Davide Giuseppe, Astegiano, Marco   +1 more
openaire   +2 more sources

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. [PDF]

J Crohns Colitis, 2022
Smith PJ, Critchley L, Storey D, Gregg B, Stenson J, Kneebone A, Rimmer T, Burke S, Hussain S, Yi Teoh W, Vazeille S, Serna S, Steel A, Derbyshire E, Collins P, Dibb M, Flanagan P, Probert C, Verma AM, Subramanian S.   +19 more
europepmc   +1 more source

Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis. [PDF]

J Dermatol, 2022
Morita A, Nishikawa K, Yamada F, Yamanaka K, Nakajima H, Ohtsuki M.   +5 more
europepmc   +1 more source